Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingEarly phase 1interventionalRules rewrite

Early phase 1: testing Tirzepatide for Endometrial Cancer

LCCC2415 examines the antiproliferative effect of tirzepatide on the endometrium of endometrial cancer (EC). This is a pre-operative window clinical study.

Official registry: https://clinicaltrials.gov/study/NCT07065552 · UNC Lineberger Comprehensive Cancer Center · enrollment listed as 20

What this phase means

Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Tirzepatide. The registry lists allocation as na. LCCC2415 examines the antiproliferative effect of tirzepatide on the endometrium of endometrial cancer (EC).

They plan to enroll about 20 people at Chapel Hill. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Pre-Operative Window Study of Tirzepatide in Obesity-Driven Endometrial Cancer

Interventions: Tirzepatide

Primary outcome (registry wording): Change in Proliferation

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Women only
  • Current diagnosis of endometrioid histology cancer and scheduled to undergo hysterectomy and staging
  • Agree to comply with all required study assessments and visits including internet capabilities
  • Age ≥ 18 at the time of consent
  • Body mass index of ≥30 kg/m2
  • Presumed clinically early-stage disease (disease confined to uterus only)
  • ECOG ≤ 2 or Karnofsky Performance Status of \> 50

Public study contact (from the registry)

Luz Cuaboy

+1 919-966-4432

luz_cuaboy@med.unc.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-…

There is evidence that early and aggressive treatment with antiretroviral drugs can prevent the loss of immune cell function that accompanies HIV infection. This study will use leukapheresis (drawing blood, separating out the white cells and returning the blood to the patient) to obtain blood cells from HIV-infected patients in either the acute or chronic stage of infection who are being treated with early highly active antiretroviral therapy (HAART).

NCT00039689 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

RecruitingNot a traditional drug phaseBethesda, Maryland
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection

This study will investigate HIV infection and associated conditions by monitoring infected patients. The study will also serve as a means for recruiting HIV-infected individuals to NIAIDs ongoing clinical and laboratory studies and supporting the institute s infectious disease training program by providing Infectious Disease fellows with ongoing training in the management of HIV infection.

NCT00789009 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

FAQ about this NCT record

Is NCT07065552 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07065552?

Early phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07065552?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary